Back

SGLT2 inhibitor treatment in patients with cardiac amyloidosis

13 May 2024 (16:17 - 16:25)
Organised by: Logo
Congress Presentation Part of: Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment Pharmacotherapy HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Daniel Lavall

University Hospital Leipzig, Leipzig (Germany)

6 More presentations in this session

Presentation thumbnail
International prevalence of transthyretin amyloid cardiomyopathy in high-risk patients with heart failure and preserved or mildly reduced ejection fraction
Doctor S. Yun Viladomat (Hospitalet De Llobregat, ES)
Abstract Slides Video
Presentation thumbnail
Age- and sex-related trends in transthyretin amyloid cardiomyopathy prevalence in older patients with unexplained hypertrophic cardiomyopathy
Professor R. Barriales-Villa (Coruna, A, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic importance of the 6-minute walk test in transthyretin cardiac amyloidosis
Doctor A. Ioannou (Greater London, GB)
Abstract Slides Video
Presentation thumbnail
Diverse presentations of transthyretin cardiac amyloidosis beyond heart failure with preserved ejection fraction
Miss A. Achten (Maastricht, NL)
Abstract Slides Video
Presentation thumbnail
Cardiac manifestations as precursors to ATTR amyloidosis diagnosis: results from the multi-country OverTTuRe study
Doctor K. Jarbrink (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Amyloid cardiomyopathy: epidemiology, diagnosis, prognostic and treatment
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 16:17 CET
You may be interested in
thumbnail
Congress Presentation
SGLT2 inhibitors in patients with amyloidosis and heart failure: a worldwide retrospective cohort study
thumbnail
Congress Presentation
SGLT2i on transthyretin amyloid cardiomyopathy - a new drug for an under-recognized cardiomyopathy
thumbnail
Congress Presentation
Potential hematopoietic effects of SGLT2 inhibitors in patients with cardiac amyloidosis.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources